company background image
BLFS logo

BioLife Solutions NasdaqCM:BLFS Stock Report

Last Price

US$26.60

Market Cap

US$1.2b

7D

10.6%

1Y

129.1%

Updated

06 Nov, 2024

Data

Company Financials +

BioLife Solutions, Inc.

NasdaqCM:BLFS Stock Report

Market Cap: US$1.2b

BLFS Stock Overview

Develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

BLFS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BioLife Solutions, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioLife Solutions
Historical stock prices
Current Share PriceUS$26.60
52 Week HighUS$27.36
52 Week LowUS$9.92
Beta1.87
11 Month Change11.06%
3 Month Change16.97%
1 Year Change129.11%
33 Year Change-46.38%
5 Year Change82.32%
Change since IPO-95.10%

Recent News & Updates

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Recent updates

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

BioLife: What The Future Holds

Oct 19

BioLife Solutions COO Roderick de Greef to retire

Oct 03

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Sep 27
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

BLFSUS Life SciencesUS Market
7D10.6%3.7%-0.8%
1Y129.1%18.9%31.5%

Return vs Industry: BLFS exceeded the US Life Sciences industry which returned 18.9% over the past year.

Return vs Market: BLFS exceeded the US Market which returned 31.5% over the past year.

Price Volatility

Is BLFS's price volatile compared to industry and market?
BLFS volatility
BLFS Average Weekly Movement7.3%
Life Sciences Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.8%

Stable Share Price: BLFS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BLFS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987412Rod de Greefwww.biolifesolutions.com

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

BioLife Solutions, Inc. Fundamentals Summary

How do BioLife Solutions's earnings and revenue compare to its market cap?
BLFS fundamental statistics
Market capUS$1.20b
Earnings (TTM)-US$63.55m
Revenue (TTM)US$139.96m

8.8x

P/S Ratio

-19.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLFS income statement (TTM)
RevenueUS$139.96m
Cost of RevenueUS$89.11m
Gross ProfitUS$50.85m
Other ExpensesUS$114.40m
Earnings-US$63.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 12, 2024

Earnings per share (EPS)-1.38
Gross Margin36.33%
Net Profit Margin-45.40%
Debt/Equity Ratio6.6%

How did BLFS perform over the long term?

See historical performance and comparison